Anti-TNF-alpha therapy and systemic vasculitis

32Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

TNF-α is a pleiotropic cytokine, which plays a major role in the pathogenesis of numerous autoimmune and/or inflammatory systemic diseases. Systemic vasculitis constitutes a group of rare diseases, characterized by inflammation of the arterial or venous vessel wall, causing stenosis and thrombosis. Treatment of the different type of vasculitis mainly relies on steroids and immunosuppressive drugs. In case of refractory or relapsing diseases, however, a second line of treatment may be required. Anti-TNF-α drugs have been used in this setting during the last 15 years with inconsistent results. We reviewed herein the use of anti-TNF-α therapy in different kind of vasculitis and concluded that, except for Behcet's disease, this therapeutic option has not demonstrated significant improvement in the treatment of vasculitis. © 2014 Pierre-André Jarrot and Gilles Kaplanski.

Cite

CITATION STYLE

APA

Jarrot, P. A., & Kaplanski, G. (2014). Anti-TNF-alpha therapy and systemic vasculitis. Mediators of Inflammation. Hindawi Publishing Corporation. https://doi.org/10.1155/2014/493593

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free